<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110093</url>
  </required_header>
  <id_info>
    <org_study_id>CZ-REGONIVO</org_study_id>
    <nct_id>NCT04110093</nct_id>
  </id_info>
  <brief_title>Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer</brief_title>
  <official_title>The Efficacy and Safety of Regorafenib Plus PD-1 Inhibitor as Third-line Therapy in Advanced Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate efficacy and safety of the combination of regorafenib and
      nivolumab as third-line or later therapy in patients with microsatellite stable (MSS)
      colorectal cancer (CRC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months</time_frame>
    <description>Time from treatment beginning until disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months</time_frame>
    <description>Time from treatment beginning until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>Through study completion, an average of 1 months</time_frame>
    <description>Incidence of Treatment-related adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Immunotherapy Combination treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All colorectal cancer patients received regorafenib plus PD-1 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib and PD-1 inhibitor</intervention_name>
    <description>All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).</description>
    <arm_group_label>Immunotherapy Combination treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced Colorectal Cancer diagnosed histologically;

          -  Patients with microsatellite stable (MSS)

          -  Patients have no any standard choice after multiple line of therapy( ≥ 2 lines);

          -  Expected survival ≥ 3 month;

          -  ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥
             90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of
             normal (ULN); Liver ALT and AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 ×
             ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min

        Exclusion Criteria:

          -  Patient still has standard treatment therapy based on NCCN guidance;

          -  Patient can not comply with research program requirements or follow-up;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhan Wang</last_name>
      <phone>+86-13916229609</phone>
      <email>13916229609@139.com</email>
    </contact>
    <investigator>
      <last_name>Yuan-Sheng Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Yuan-Sheng Zang</investigator_full_name>
    <investigator_title>Head of Medical Oncology Department</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Regorafenib</keyword>
  <keyword>Nivoluamb</keyword>
  <keyword>microsatellite stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

